Loading
JCOG0403 gave the first prospective evidence that stereotactic lung radiotherapy works in patients who could have had surgery, not only in those too frail for it, and set the 48 Gy in four fractions schedule used across Japan.
JCOG0403 was a two-cohort phase 2 trial of stereotactic body radiotherapy (48 Gy in four fractions) for stage IA non-small-cell lung cancer, enrolling 65 operable and 104 inoperable patients. Three-year overall survival was 76.5 percent in the operable cohort and 59.9 percent in the inoperable one, with acceptable toxicity (Nagata and colleagues, International Journal of Radiation Oncology Biology Physics 2015). It prompted the randomised comparisons of surgery and stereotactic radiotherapy that followed.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
169 enrolled.
95% CI 64.0-85.1 · 95% CI 49.6-68.8
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survival at 3 yearsprimary | Operable patients, SBRT 48 Gy in 4 fractions | 64 | 76.5% | - | - | link |
| Inoperable patients, SBRT 48 Gy in 4 fractions | 100 | 59.9% |
Shares Resectable stage I to III non-small-cell lung cancer, SBRT / SABR (stereotactic radiotherapy), Non-small-cell lung cancer and the tag radiation-wave2.
Shares SBRT / SABR (stereotactic radiotherapy) and the tag radiation-wave2.
Shares Non-small-cell lung cancer and the tag radiation-wave2.
Shares SBRT / SABR (stereotactic radiotherapy) and the tag radiation-wave2.
Shares Non-small-cell lung cancer and the tag radiation-wave2.
Shares Resectable stage I to III non-small-cell lung cancer, SBRT / SABR (stereotactic radiotherapy).
Shares Resectable stage I to III non-small-cell lung cancer, SBRT / SABR (stereotactic radiotherapy).
Shares Japan Clinical Oncology Group (JCOG), Non-small-cell lung cancer.